Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

related to degree

  • Patricelli, Matt, Ph.D. in Biology, Scripps Research 1996 - 2000

authors

  • Cravatt, Benjamin
  • Demarest, K.
  • Patricelli, Matt
  • Bracey, M. H.
  • Giang, D. K.
  • Martin, B. R.
  • Lichtman, A. H.

publication date

  • July 2001

journal

  • Proceedings of the National Academy of Sciences of the United States of America  Journal

abstract

  • The medicinal properties of marijuana have been recognized for centuries, but clinical and societal acceptance of this drug of abuse as a potential therapeutic agent remains fiercely debated. An attractive alternative to marijuana-based therapeutics would be to target the molecular pathways that mediate the effects of this drug. To date, these neural signaling pathways have been shown to comprise a cannabinoid receptor (CB(1)) that binds the active constituent of marijuana, tetrahydrocannabinol (THC), and a postulated endogenous CB(1) ligand anandamide. Although anandamide binds and activates the CB(1) receptor in vitro, this compound induces only weak and transient cannabinoid behavioral effects in vivo, possibly a result of its rapid catabolism. Here we show that mice lacking the enzyme fatty acid amide hydrolase (FAAH(-/-)) are severely impaired in their ability to degrade anandamide and when treated with this compound, exhibit an array of intense CB(1)-dependent behavioral responses, including hypomotility, analgesia, catalepsy, and hypothermia. FAAH(-/-)-mice possess 15-fold augmented endogenous brain levels of anandamide and display reduced pain sensation that is reversed by the CB(1) antagonist SR141716A. Collectively, these results indicate that FAAH is a key regulator of anandamide signaling in vivo, setting an endogenous cannabinoid tone that modulates pain perception. FAAH may therefore represent an attractive pharmaceutical target for the treatment of pain and neuropsychiatric disorders.

subject areas

  • Amidohydrolases
  • Animals
  • Arachidonic Acids
  • Behavior, Animal
  • Brain
  • Cannabinoids
  • Endocannabinoids
  • Ethanolamines
  • Mice
  • Mice, Knockout
  • Pain Threshold
  • Polyunsaturated Alkamides
  • Receptors, Cannabinoid
  • Receptors, Drug
  • Signal Transduction
scroll to property group menus

Identity

PubMed Central ID

  • PMC55427

International Standard Serial Number (ISSN)

  • 0027-8424

Digital Object Identifier (DOI)

  • 10.1073/pnas.161191698

PubMed ID

  • 11470906
scroll to property group menus

Additional Document Info

start page

  • 9371

end page

  • 9376

volume

  • 98

issue

  • 16

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support